PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
about
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disordersImpact of apolipoprotein E on Alzheimer's diseaseNatural Phytochemicals in the Treatment and Prevention of Dementia: An OverviewMolecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisalNon-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium?Insulin: an emerging treatment for Alzheimer's disease dementia?Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseNew pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsNeuroinflammation in Alzheimer's diseaseNeuronal seipin knockout facilitates Aβ-induced neuroinflammation and neurotoxicity via reduction of PPARγ in hippocampus of mouseMHC mismatch inhibits neurogenesis and neuron maturation in stem cell allograftsAlzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and GammaAlzheimer's disease and type 2 diabetes via chronic inflammatory mechanismsCannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvementA network-based classification model for deriving novel drug-disease associations and assessing their molecular actionsStructural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.Expression of ALS-linked TDP-43 mutant in astrocytes causes non-cell-autonomous motor neuron death in ratsInsulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.The relationship of diet and acne: A reviewIdentification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathwaysProfiling the genes affected by pathogenic TDP-43 in astrocytesRole of the adipose PPARγ-adiponectin axis in susceptibility to stress and depression/anxiety-related behaviors.Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach.Alzheimer's disease: a healthcare burden of epidemic proportion.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trialsThiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution.Using genetics to enable studies on the prevention of Alzheimer's diseaseCurrent and emerging drug treatment options for Alzheimer's disease: a systematic review.Nuclear receptors in neurodegenerative diseases.A mitocentric view of Alzheimer's disease suggests multi-faceted treatmentsRole of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapiesMitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.Effects of low doses of pioglitazone on resting-state functional connectivity in conscious rat brain.Nuclear receptors as therapeutic targets for Alzheimer's diseaseWIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid β1-42 effects on astrocytes in primary culture.Alzheimer's disease and the amyloid cascade hypothesis: a critical review.Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's DiseasePPARγ-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats.Reactive astrocytes secrete lcn2 to promote neuron death.
P2860
Q24562763-99A8BCDF-D3AB-4439-B9A5-7999C60C6C5DQ24567759-E04CAD39-3453-4E2B-8CFB-9E11860C9D6FQ26750581-1402AF78-8F14-44EA-AF45-D1C71E20125AQ26783344-65F16C23-A69A-4B7B-9428-CF934C1A09ACQ26822022-7CB00A8B-529A-40A2-B7B9-F98D06F11B06Q26827376-004BA89C-261C-41A5-A276-17536B470C74Q26829899-F5F0DDFC-480F-4DBF-8D82-1DFC4E06EBD6Q26866006-F54C03C1-14FC-4236-99A5-4B416F88D9B9Q27004226-69080602-67EB-4E15-A1E3-E4F587AD796DQ27303098-095A999B-9E39-42EA-9E1A-F61141E30CC1Q27313884-F8931CE7-6653-429A-9383-F1B7912BB8F7Q28075617-5E611B3C-0670-40DC-A5ED-9FBB11EF91C8Q28086892-6FD809C8-AF90-4B47-A721-9F872C230CFEQ28394506-7CA92D8D-5004-4FF0-BB2B-11EB61177431Q28544627-180DCBA6-2E69-4F88-96A9-804E30910847Q30418832-8F8BDBB4-2845-4F50-BD75-8E6CC53E7075Q30575773-4943657F-253B-4A1F-8EDD-39343DB72661Q33628048-82F0375B-722F-4238-ACC6-5DB68F5266FFQ33718918-0DE1A6BB-B4CA-419F-BB0D-DAC7950562F3Q33762512-55693E64-9481-4492-8F5E-B46BCED3EA13Q33789456-AA7EB7C5-DA52-46A9-9BA6-983DB13CFD74Q33790412-37407D1E-83FF-44FC-BD85-02ECDCB96E1FQ33921641-8DF9CBB2-933B-4BE9-BEFB-E60A3DFE61EAQ33932371-5CE1D137-99FB-4295-A0B7-60AD2CE6123EQ34014237-8E009D5D-9329-4BF5-B933-4F54DB1B9C91Q34020483-9F0506EF-8965-4B67-8383-EF3858F92DB0Q34038890-719D5E0B-DFC7-4FC1-8B7C-DE2EA926CAC2Q34222721-911E504D-03BB-4419-9DF4-157571461C39Q34580020-AEA14802-B609-4C7E-AE94-7EC5595C4EECQ34902708-3D99A9E8-7282-4527-ABA5-2CDD90B948A4Q34974167-071E7FCA-8966-4D8D-819E-898272547167Q34994270-A17CFEF3-9522-44D1-B987-0367D9BAF638Q35073600-18E63C75-1E13-4E78-B6B0-4A4ED1535289Q35165186-1AD0C512-7ED1-495A-8C2E-BF4B3C540283Q35601542-067BC4FC-03A9-4C3F-B3E3-BCB27ADB883CQ35855587-E507A065-3B2F-4273-B9EB-1CC92A5A7DFBQ36063631-C08B7030-210E-46BB-87B8-32CF2D552FE5Q36081889-D5374359-DC0F-4569-A852-0B18FAE8B4F5Q36495190-C918B595-62C5-428F-9A42-184A3AE15C0FQ36673303-D0C507AA-4EFB-43B1-B37A-3247D23348CF
P2860
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
@en
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
@nl
type
label
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
@en
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
@nl
prefLabel
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
@en
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
@nl
P2093
P2860
P1433
P1476
PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
@en
P2093
Gary Landreth
Michael Heneka
Qingguang Jiang
Shweta Mandrekar
P2860
P2888
P304
P356
10.1016/J.NURT.2008.05.003
P577
2008-07-01T00:00:00Z
P5875
P6179
1030614809